Trailhead Biosystems Secures $20 Million to Drive Innovation and Accelerate Growth
BEACHWOOD, Ohio, May 6, 2025 /CNW/ --Trailhead Biosystems Inc. (www.trailbio.com), a biotechnology company advancing human cell innovation, has secured $20 million in financing. Trailhead specializes in precisely differentiating induced pluripotent stem cells (iPSCs) into functional human cell types—unlocking new possibilities for research and cell therapy. Through its proprietary High-Dimensional Design of Experiments (HD-DoE®) platform, Trailhead optimizes differentiation with exceptional accuracy, enabling scalable solutions for both drug discovery and regenerative medicine. The investment, led by MAK Capital with participation from additional investors, comes at a critical phase of Trailhead's growth, enabling expansion in personnel, manufacturing and strategic partnerships.
Accelerating Growth in Research Markets
The funding will enhance Trailhead's rapidly expanding portfolio of iPSC-derived cells for research applications, advancing preclinical drug discovery and disease modeling. The company recently introduced TrailBio® Vascular Leptomeningeal Cells (VLMCs) for blood-brain barrier research, addressing a critical need in neuroscience and drug delivery. Upcoming product introductions include iPSC-derived pancreatic islets, hepatocytes, dopaminergic neurons and hematopoietic progenitors, providing researchers with highly specialized human cell models to drive breakthroughs.
Beyond its off-the-shelf offerings, Trailhead remains dedicated to custom cell differentiation services, enabling scientists to refine existing models or develop novel cell types with precise biological fidelity.
As the FDA shifts toward human-based lab models as alternatives to animal testing, Trailhead's human-relevant cell products provide a scalable and predictive solution for modern drug development and safety testing. These new approaches enhance high-throughput screening, disease modeling and the development of organoid and organ-on-a-chip research platforms.
Strengthening Therapeutic Partnerships
This funding also strengthens Trailhead's ability to support therapeutic partners, driving innovation and scalability in cell-based therapies. Investments in infrastructure and personnel will enhance manufacturing capabilities, streamline production workflows and deepen collaborations with leading industry partners in regenerative medicine.
"This investment allows us to further advance how iPSCs are differentiated into precise human cell types for both drug discovery and therapeutic development," said Jan Jensen, Ph.D., CEO/CSO and founder of Trailhead Biosystems. "By optimizing scalable differentiation processes, we are enabling researchers to accelerate discovery and develop more predictive models, while also supporting the next generation of cell-based therapies."
About Trailhead Biosystems
Trailhead Biosystems, Inc. is pioneering the informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CEO/CSO Dr. Jan Jensen during his tenure as an endowed professor at the Cleveland Clinic.
Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design of Experiments (HD-DoE®) platform. HD-DoE® integrates advanced mathematical modeling with high-throughput robotic manufacturing.
Trailhead operates facilities in Beachwood, Ohio, with a business development office in Kendall Square, Cambridge, MA.
For more information, please contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
DENARIUS METALS ANNOUNCES BROKERED LIFE OFFERING OF UNITS
, June 9, 2025 /CNW/ - Denarius Metals Corp. (Cboe CA: DMET) (OTCQX: DNRSF) ("Denarius Metals" or the "Company") announced today that it has entered into an agreement with Stifel Nicolaus Canada Inc. (" Stifel Canada") to act as lead agent and bookrunner on behalf of a syndicate of agents (collectively, the "Agents") in connection with a "best efforts" agency basis private placement (the "Offering") for the sale of up to 18,182,000 Units of the Company at a price of C$0.55 per Unit (the "Offering Price") for gross proceeds to the Company of up to C$10,000,100. Each Unit will consist of one common share in the capital of the Company and one common share purchase warrant ("Warrant"). Each Warrant will entitle the holder to purchase one common share of the Company at a price of CA$0.66 per common share at any time on or before that date which is 60 months after the closing date. It is anticipated that the closing of the Offering will occur on or prior to June 19, 2025. The Units will be offered to purchasers by way of the "listed issuer financing" exemption under Part 5A (the "LIFE Exemption") of National Instrument 45-106 – Prospectus Exemptions ("NI 45-106") in all the provinces of Canada other than Québec. Upon closing of the Offering, the Units are expected to be immediately freely tradeable under applicable Canadian securities legislation. The Company will grant to the Agents an option, exercisable up to three business days prior to the closing date, to purchase for resale up to an additional 15% of Units at the Offering Price for additional gross proceeds of up to C$1,500,015. The Company intends to use the net proceeds of the Offering to fund its projects in Spain, including the advancement of scoping and other studies, and site administration costs at its Lomero and Toral Projects, capital contributions related to certain restart activities and site administration costs at the Aguablanca Project, to fund certain exploration and development expenditures at its Zancudo Project in Colombia and for general corporate purposes and working capital of the Company. Completion of the Offering is subject to shareholder and regulatory approvals, as applicable, including Cboe Canada. As the number of securities issuable in the Offering (calculated on a fully diluted basis) is more than 25% of the total number of the current total number of issued and outstanding common shares (the "Outstanding Shares") and the Offering Price is less than the closing price of the common shares on the day preceding the Company's price reservation, to proceed with the Offering the Company requires approval from shareholders representing a majority of the Outstanding Shares held by disinterested shareholders. The Company intends to satisfy Cboe Canada's shareholder approval requirement by obtaining a written resolution approving the Offering from the holders of at least 50% of the Outstanding Shares entitled to vote thereon. There is an offering document related to the Offering that can be accessed under the Company's profile at and at the Company's website at Prospective investors should read this offering document before making an investment decision. No U.S. Offering or Registration This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. About Denarius Metals Denarius Metals is a Canadian junior company engaged in the acquisition, exploration, development and eventual operation of precious metals and polymetallic mining projects in high-grade districts in Colombia and Spain. Denarius Metals is listed on Cboe Canada where it trades under the symbol "DMET". The Company also trades on the OTCQX Market in the United States under the symbol "DNRSF". In Colombia, Denarius Metals recently commenced mining operations at its 100%-owned Zancudo Project, a high-grade gold-silver deposit, which includes the historic producing Independencia mine, located in the Cauca Belt, about 30 km southwest of Medellin. In Spain, Denarius Metals has interests in three projects focused on in-demand critical minerals. The Company owns a 21% interest in Rio Narcea Recursos, S.L. and is the operator of its Aguablanca Project, which has recently been recognized by the EU as a Strategic Project. The Aguablanca Project comprises a turnkey 5,000 tonnes per day processing plant and the rights to exploit the historic producing Aguablanca nickel-copper mine, located in Monesterio, Extremadura. Denarius Metals also owns a 100% interest in the Lomero Project, a polymetallic deposit located on the Spanish side of the prolific copper rich Iberian Pyrite Belt, approximately 88 km southwest of the Aguablanca Project, and a 100% interest in the Toral Project, a high-grade zinc-lead-silver deposit located in the Leon Province, Northern Spain. Additional information on Denarius Metals can be found on its website at and by reviewing its profile on SEDAR+ at Cautionary Statement on Forward-Looking Information This news release contains "forward-looking information", which may include, but is not limited to, statements with respect to anticipated business plans or strategies, including the Offering, shareholders, regulatory and Cboe Canada approvals of the Offering, and the use of proceeds of the Offering. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Denarius Metals to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in the Company's Annual Information Form dated March 31, 2025 which is available for view on SEDAR+ at Forward-looking statements contained herein are made as of the date of this press release and Denarius Metals disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. SOURCE Denarius Metals Corp.
Cision Canada
an hour ago
- Cision Canada
AURORA CANNABIS CHS CLASS ACTION CERTIFIED
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. . Sotos Class Actions 55 University Avenue, Suite 600 Toronto, ON M5J 2H7 [email protected] 1-877-294-9747 (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
Cision Canada
3 hours ago
- Cision Canada
TALON METALS ANNOUNCES UPSIZED $39 MILLION FINANCING COMPRISED OF $25 MILLION BROKERED PRIVATE PLACEMENT AND CONCURRENT $14 MILLION NON-BROKERED PRIVATE PLACEMENT
ROAD TOWN, Tortola, , June 9, 2025 /CNW/ - Talon Metals Corp. (TSX: TLO) (OTC Pink: TLOFF) (" Talon" or the " Company") is pleased to announce that as a result of strong investor demand, the Company has amended its agreement with Canaccord Genuity Corp. (" Canaccord Genuity") on behalf of a syndicate of underwriters (the " Underwriters") to increase the size of its previously announced "bought deal" private placement of units of the Company (the " LIFE Units") to raise gross proceeds of $25,300,000 (the " LIFE Offering"), consisting of 115,000,000 LIFE Units at a price of $0.22 per LIFE Unit (the " Offering Price"). Concurrent with the LIFE Offering, the Company plans to complete a non-brokered private placement of up to 62,227,274 units of the Company (the " Non-LIFE Units" and, together with the LIFE Units, the " Units") at the Offering Price per Non-LIFE Unit for aggregate gross proceeds of up to approximately $13,690,000 (the " Non-LIFE Offering" and, together with the LIFE Offering, the " Offerings"). The Non-LIFE Units will be issued on the same terms as the LIFE Units. The Non-LIFE Units may be offered to purchasers resident in Canada pursuant to applicable prospectus exemptions, other than the Listed Issuer Financing Exemption (as defined below), in accordance with applicable laws, and may also be offered in other qualifying jurisdictions outside of Canada on a private placement basis pursuant to relevant prospectus or registration exemptions in accordance with applicable laws. Any securities issued under the Non-LIFE Offering to purchasers resident in Canada will be subject to a hold period in accordance with applicable Canadian securities laws, expiring four months and one day following the issue date of the Non-LIFE Units. The Non-LIFE Offering will be completed with certain directors, officers and affiliates of Pallinghurst Nickel International Ltd. Each Unit will be comprised of one common share of the Company (a " Common Share") and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a " Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share (a " Warrant Share") at a price of $0.28 per Warrant Share for a period of 36 months from the closing of the LIFE Offering or Non-LIFE Offering, as applicable. In the event that the closing price of the Common Shares on the Toronto Stock Exchange (the " TSX") (or such other Canadian stock exchange on which the Common Shares are then listed) for twenty (20) consecutive trading days exceeds $0.56, the Company may, within 10 business days of the occurrence of such event, deliver a notice (including by way of a news release) to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice. The LIFE Units will be offered pursuant to Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the " Listed Issuer Financing Exemption"), to purchasers resident in Canada (other than the province of Québec), and in other qualifying jurisdictions outside of Canada that are mutually agreed to by the Company and the Underwriters on a private placement basis pursuant to relevant prospectus or registration exemptions in accordance with applicable laws. The securities issued under the LIFE Offering to Canadian subscribers will not be subject to a hold period in Canada. There is an amended and restated offering document related to the LIFE Offering (the " Offering Document") that can be accessed under the Company's profile on SEDAR+ at and on the Company's website at Prospective investors should read the Offering Document before making an investment decision. The Company intends to use the net proceeds from the Offerings to advance the Tamarack Nickel Project and for general and administrative expenses and working capital purposes, as further described in the Offering Document. The Offerings are expected to close on or about June 19, 2025, or such other date as the Company and Canaccord Genuity may agree (the " Closing Date"). The Non-LIFE Offering may close on a date subsequent to or prior to the closing date of the LIFE Offering at the discretion of the Company. The Offerings are subject to the Company receiving all necessary regulatory approvals, including the approvals of the TSX. The closing of the LIFE Offering is not conditional upon closing of the Non-LIFE Offering, and the closing of the Non-LIFE Offering is not conditional upon closing of the LIFE Offering. The Units (and the underlying securities) to be offered pursuant to the Offerings have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the " U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About Talon Talon is a TSX-listed base metals company in a joint venture with Rio Tinto on the high-grade Tamarack Nickel-Copper-Cobalt Project located in central Minnesota. Talon's shares are also traded in the US over the OTC market under the symbol TLOFF. The Tamarack Nickel Project comprises a large land position (18km of strike length) with additional high-grade intercepts outside the current resource area. Talon has an earn-in right to acquire up to 60% of the Tamarack Nickel Project and currently owns 51%. Talon is focused on (i) expanding and infilling its current high-grade nickel mineralization resource prepared in accordance with NI 43-101 to shape a mine plan for submission to Minnesota regulators, and (ii) following up on additional high-grade nickel mineralization in the Tamarack Intrusive Complex. Talon has a neutrality and workforce development agreement in place with the United Steelworkers union. Talon's Beulah Mineral Processing Facility in Mercer County was selected by the US Department of Energy for US$114.8 million funding grant from the Bipartisan Infrastructure Law and the US Department of Defense awarded Talon a grant of US$20.6 million to support and accelerate Talon's exploration efforts in both Minnesota and Michigan. Talon has well-qualified experienced exploration, mine development, external affairs and mine permitting teams. Forward-Looking Statements This news release contains certain "forward-looking statements". All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements reflect the current expectations and beliefs of the Company based on information currently available to the Company. Such forward-looking statements include statements relating to the Offerings, including the completion and anticipated timing for completion of the Offerings, the potential size of the Offerings, the Company's intended use of the net proceeds of the Offerings, the receipt of all necessary regulatory approvals, including the approvals of the TSX, and the Company's exploration and development plans. Forward-looking statements are subject to significant risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
